These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 34667077)

  • 1. MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas.
    Wang QW; Sun LH; Zhang Y; Wang Z; Zhao Z; Wang ZL; Wang KY; Li GZ; Xu JB; Ren CY; Ma WP; Wang HJ; Li SW; Zhu YJ; Jiang T; Bao ZS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34667077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
    Zhou J; Pei X; Yang Y; Wang Z; Gao W; Ye R; Zhang X; Liu J; Liu Z; Yang X; Tao J; Gu C; Hu W; Chan FL; Li X; Mao J; Wu D
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
    Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma.
    Tong L; Li J; Li Q; Wang X; Medikonda R; Zhao T; Li T; Ma H; Yi L; Liu P; Xie Y; Choi J; Yu S; Lin Y; Dong J; Huang Q; Jin X; Lim M; Yang X
    Theranostics; 2020; 10(13):5943-5956. PubMed ID: 32483429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
    Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients.
    Liu Y; Carlsson R; Ambjørn M; Hasan M; Badn W; Darabi A; Siesjö P; Issazadeh-Navikas S
    J Neurosci; 2013 Aug; 33(35):14231-45. PubMed ID: 23986257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
    Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H
    Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma.
    Yi K; Cui X; Liu X; Wang Y; Zhao J; Yang S; Xu C; Yang E; Xiao M; Hong B; Fang C; Kang C; Tan Y; Wang Q
    Front Immunol; 2021; 12():802795. PubMed ID: 35069587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
    Lamano JB; Lamano JB; Li YD; DiDomenico JD; Choy W; Veliceasa D; Oyon DE; Fakurnejad S; Ampie L; Kesavabhotla K; Kaur R; Kaur G; Biyashev D; Unruh DJ; Horbinski CM; James CD; Parsa AT; Bloch O
    Clin Cancer Res; 2019 Jun; 25(12):3643-3657. PubMed ID: 30824583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell Function.
    Ahn HK; Kim S; Kwon D; Koh J; Kim YA; Kim K; Chung DH; Jeon YK
    Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31480591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages.
    Zhu Z; Zhang H; Chen B; Liu X; Zhang S; Zong Z; Gao M
    Front Immunol; 2020; 11():588552. PubMed ID: 33329573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.
    Dai L; Xiao J; Li X; Tao Y; Zhou P; Lyu L; Shi Z; Liang X; Jia Z; Jiang S
    J Gene Med; 2024 May; 26(5):e3685. PubMed ID: 38686653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR7 activation evokes the anti-PD-L1 antibody against glioblastoma by remodeling CXCL12-mediated immunity.
    Liu CC; Yang WB; Chien CH; Wu CL; Chuang JY; Chen PY; Chu JM; Cheng SM; Qiu LY; Chang YC; Hwang DY; Huang CY; Lee JS; Chang KY
    Cell Death Dis; 2024 Jun; 15(6):434. PubMed ID: 38898023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
    Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G
    J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 18. A Systematic Review of the Tumor-Infiltrating CD8
    Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():734956. PubMed ID: 34603316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
    Heynckes S; Daka K; Franco P; Gaebelein A; Frenking JH; Doria-Medina R; Mader I; Delev D; Schnell O; Heiland DH
    BMC Cancer; 2019 Feb; 19(1):117. PubMed ID: 30709339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the Clinical Significance of PD-1/PD-Ls Expression and Methylation in Patients With Low-Grade Glioma.
    Mei J; Cai Y; Xu R; Yang X; Zhou W; Wang H; Liu C
    Technol Cancer Res Treat; 2021; 20():15330338211011970. PubMed ID: 33955303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.